News Focus
News Focus
Followers 232
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: None

Wednesday, 07/26/2017 6:22:25 PM

Wednesday, July 26, 2017 6:22:25 PM

Post# of 447701
Amarin and Amarin longs should carefully read Gottlieb's statement before his testimony tomorrow in front of the House Judiciary Committee.

His statement was carefully released and timed with the market today:
https://judiciary.house.gov/wp-content/uploads/2017/07/Gottlieb-FDA-Testimony.pdf

You should also note the considerable amount of time he spends on Citizen Petitions.

While most of the witness have come to discuss how the World is deprived of low cost generic drugs, I would not exclude the possibility Amarin/Vascepa/NCE/FDA/Watson leak doesn't surface.

Tomorrow Vascepa isn't covered under any Hatch-Waxman exclusivity and this is VERY VERY wrong.

Here's a link to the hearing:
https://judiciary.house.gov/hearing/antitrust-concerns-fda-approval-process/

Perhaps Gottlieb is ready for an assist at swinging at Windmill's?

It's not completely odd for Amarin to announce Q2 today, but it's a day early for may range.

BB

Mr. McGee, don't make me angry. You wouldn't like me when I'm angry---David Banner

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News